Not FDA-approved1Evidence: Limited human dataGut and digestion · Tissue repair and wound healing

BPC-1571

Also called Body protection compound 157, Bepecin, PL 147361

Key takeaway

BPC-157 is a 15-amino-acid peptide first described by researchers in 1993, and most research on it has been done in rodents and laboratory models.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved medicine containing it in any country it searched.1 Published human data are limited to a few small, short studies. FDA concluded they do not show that it works for the one use it evaluated, ulcerative colitis, and are not enough to describe its safety.1 FDA staff recommended against adding BPC-157 to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides that licensed pharmacies may compound under set conditions without federal enforcement action while FDA’s rulemaking continues.1,7,8

BPC-157 at a glance

What it isA 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1
FDA statusNot FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,7,8
Human evidenceA few small, short human studies, including one randomized ulcerative colitis study reported only as a meeting abstract. Two registered trials had no posted results in the cited registry records.1,3,5
Sport statusFDA’s briefing notes that BPC-157 is on the World Anti-Doping Agency’s prohibited list under non-approved substances (S0), as FDA checked in December 2025.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is BPC-157?

BPC-157 is a peptide made of 15 amino acids. FDA’s briefing describes it as a fragment of a larger protein, called body protection compound, that was originally isolated from human gastric juice. It is also known as bepecin or PL 14736.1

Researchers first described BPC-157 in 1993 and have studied it mainly for proposed protective and healing effects in animals. FDA could not determine how long it has been used in pharmacy compounding.1

FDA found BPC-157 marketed in the United States as an ingredient in dietary supplement products, and found that websites promoting it most often mention digestive uses.1

How is BPC-157 thought to work?

How BPC-157 works has not been established. FDA’s briefing states that its molecular targets have not been identified and that its mechanisms of action remain poorly understood.1

Based on animal and laboratory studies, researchers have proposed that it may increase growth-factor signaling, reduce inflammatory signals, promote new blood-vessel formation, and raise nitric oxide production.1

FDA cautions that these animal findings should be interpreted carefully, because larger amounts did not produce consistently larger effects and the biological plausibility of the reported effects is hard to assess.1

What do human studies show?

FDA’s 2026 review identified five published human studies. All were small and short, and FDA found that their authors provided limited safety information.1

The only randomized, placebo-controlled study FDA found tested a BPC-157 enema for two weeks in 53 people with ulcerative colitis. It was reported only as a 2005 meeting abstract, and FDA concluded its data were inadequate to support efficacy or safety.1

No serious adverse events appear to have been reported in these studies, but FDA notes that safety monitoring was unclear for most of them. FDA found no human studies using the oral, under-the-skin, nasal or skin routes proposed for compounded products.1

FDA’s adverse-event reports include injection-site reactions, shortness of breath, and darkening of the skin and gums after BPC-157 use, but FDA could not determine whether BPC-157 caused them.1

Two newer trials are registered: a Phase 2 hamstring-strain trial and a Phase 1 rotator cuff study. Neither had posted results in the cited registry records.3,5

What the evidence base contains

  • Small, short, or incompletely reported human study One randomized, placebo-controlled study of a BPC-157 enema in 53 people with ulcerative colitis, reported only as a 2005 meeting abstract. FDA found its reported details inadequate to support efficacy or safety conclusions.1
  • Small, short, or incompletely reported human study Four other small human reports listed by FDA: enema studies in healthy volunteers, knee-pain injections in 17 people, bladder injections in 12 people with interstitial cystitis, and an intravenous safety pilot in two healthy adults.1
  • Registered trial without results A randomized Phase 2 trial in adults with an acute hamstring strain, first posted in February 2026 as recruiting, with no results posted.3
  • Registered trial without results A Phase 1 study in rotator cuff tears, listed as not yet recruiting in its September 3, 2026 registry record.5
  • Animal or laboratory research Most published research reports effects in rodent and laboratory models, including gut, liver, tendon and nerve injury models.1

Evidence-strength label: Limited human data. How this label is assigned

Is BPC-157 FDA-approved?

No. FDA’s May 2026 evaluation states that BPC-157 is not a component of any FDA-approved drug and that there is no United States Pharmacopeia monograph for it.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.7

FDA staff evaluated BPC-157 for that list for ulcerative colitis and recommended against adding it. They cited poor chemical characterization, limited safety information, a risk of immune reactions, insufficient evidence of effectiveness, and existing FDA-approved treatments for ulcerative colitis.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.2

FDA’s Pharmacy Compounding Advisory Committee discussed BPC-157 at its July 23–24, 2026 meeting. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,4,8

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS says the policy is not binding and may be revisited if safety or quality problems arise.7

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.8

The policy does not make BPC-157 an FDA-approved drug. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.8

Timeline

  1. Researchers first describe BPC-157 in the scientific literature.1
  2. A Federal Register notice announces the July advisory-committee meeting that will discuss BPC-157 and opens a public comment docket.6
  3. FDA’s compounding safety-risk page, as last updated, lists BPC-157 among withdrawn nominations and describes immune-reaction and characterization concerns.2
  4. FDA staff date their evaluation recommending that BPC-157 not be added to the 503A bulks list.1
  5. FDA’s Pharmacy Compounding Advisory Committee discusses BPC-157.4
  6. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists BPC-157 among six peptide substances used in compounding.7,8

What is still unknown?

Whether BPC-157 benefits people for any condition: none of the human studies FDA identified was a fully reported controlled trial.1

Its safety with repeated or long-term use, and how much reaches the bloodstream after oral, injected, nasal or skin use, have not been established in people.1

What is actually in products sold under the name: FDA notes that the free base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1

Whether FDA’s rulemaking will add BPC-157 to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,7,8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for BPC-157: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for BPC-157 are the records PeptideScanner has selected and published, not every registration or paper about BPC-157. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence questions

Start with the question you have

Open the cited status, reviewed human evidence, unresolved limits, or profile changes.

Evidence summary

What the cited records show

What is its status in the cited records?

Not an FDA-approved drug. FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed August 18, 2026 · Review version 1.

Review source snapshots checked August 18, 2026 · Integrity checked August 19, 2026.

A bounded review of one human safety pilot, one literature-and-patent review, and one current human trial protocol.↗↗↗

What the reviewed sources report

This source set contains a two-person uncontrolled safety pilot, a narrative review dominated by preclinical research, and a recruiting Phase 2 protocol with no posted results. It does not establish human efficacy.↗↗↗

What remains unresolved?

  • Do adequately powered controlled human trials reproduce any claimed benefit and characterize harms over meaningful follow-up?↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about BPC-157?

Manually reviewed August 18, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of one human safety pilot, one literature-and-patent review, and one current human trial protocol.213

Bottom line from this bounded source set

This source set contains a two-person uncontrolled safety pilot, a narrative review dominated by preclinical research, and a recruiting Phase 2 protocol with no posted results. It does not establish human efficacy.213

Reviewed study record

Two-person human safety pilot

Design

An IRB-approved, uncontrolled pilot measured selected laboratory values, vital signs, and participant-reported side effects over a short observation window.2

Population

Two healthy adults at one private clinic participated; both had previously received BPC-157.2

Outcomes reported

The authors reported no measurable changes in the tested biomarkers and no participant-reported side effects during the observation window.2

Limitations

Two previously exposed participants, no comparator, one site, and short follow-up cannot establish general safety or any treatment effect.2

Reviewed study record

Current hamstring-strain protocol

Design

A randomized, parallel, quadruple-masked Phase 2 protocol is listed as recruiting. The registry currently posts a study plan, not results.3

Population

The protocol estimates 120 adults with an acute MRI-confirmed grade II hamstring strain.3

Outcomes reported

Return to unrestricted sport and change in MRI-assessed injury volume are registered primary outcomes; no outcome data are posted.3

Limitations

Recruitment status and planned outcomes do not demonstrate completion, safety, or effectiveness.3

Reviewed study record

Review-level context

Design

A narrative literature-and-patent review summarizes proposed mechanisms, preclinical models, patents, toxicity discussion, and limited clinical context.1

Population

The reviewed activity is primarily drawn from preclinical models rather than controlled human trials.1

Outcomes reported

The review describes favorable findings reported across preclinical models while stating that comprehensive human clinical studies are insufficient.1

Limitations

Narrative synthesis and preclinical findings cannot substitute for controlled human evidence, and the review does not establish clinical benefit.1

Reviewed source set

  1. PubMed · 40005999Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review ↗PubMed PMID 40005999 · EFetch XML reviewed 2026-08-18 · payload SHA-256 54a98f7cbdf10ee6109915e24f031cd8c0ab34ed2d0d58d07442b65b1b59ef77
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.3390/ph18020185. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 40131143Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study ↗PubMed PMID 40131143 · EFetch XML reviewed 2026-08-18 · payload SHA-256 b8138b6d382044cd559c8274fa4c5cc83530afbdd3ba2e55ee069ce56d9a55ca
    Crossref check unavailableThe reviewed PubMed payload did not include a DOI, so this source could not be matched to a Crossref work endpoint.
  3. ClinicalTrials.gov · NCT07437547BPC 157 for Acute Hamstring Muscle Strain Repair ↗ClinicalTrials.gov history entry 1 · API v2 protocol payload · ETag 883b003/0.34.1/msyfmeiw · reviewed 2026-08-18 · payload SHA-256 12bfc8e25e906a301d3386e85ec82800566378a3b8e16cfcf78075175c8b5e57
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 2

FDA’s review focused on ulcerative colitis

FDA evaluated BPC-157 free base and acetate separately for ulcerative colitis. The briefing recommended against their inclusion on the 503A bulks list. It explicitly precedes a final agency determination; this summary does not report a final ruling. FDA PDF pp. 1, 5, 8, 9 ↗FDA PDF pp. 43, 44, 45, 46, 47 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

The human trial evidence was limited

FDA identified a 53-participant, two-week randomized study reported only in a meeting abstract. Missing endpoint, eligibility, statistical and follow-up details prevented it from supporting efficacy and safety conclusions for ulcerative colitis. FDA PDF pp. 25, 27, 28, 29 ↗

Formulation and duration limit extrapolation

The reviewed trial used a rectal enema, not the nominated suppository. FDA found no ulcerative-colitis studies using the proposed oral, subcutaneous, nasal or transdermal routes. These findings cannot establish effectiveness for tendon or sports injuries. FDA PDF pp. 1, 5, 8, 9 ↗FDA PDF pp. 25, 27, 28, 29 ↗

Safety remains inadequately characterized

FDA described insufficient clinical safety information, limited long-term data and concerns involving peptide impurities, aggregation and immune responses. Its adverse-event reports could not establish causality. FDA PDF pp. 43, 44, 45, 46, 47 ↗

Rectal-enema findings do not validate other formulations

The briefing distinguishes the studied rectal enema from the nominated suppository and other routes. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal administration in its reviewed sources. FDA PDF pp. 27, 40 ↗

Assay experiments are not human treatment studies

FDA identified laboratory plasma-metabolism reports used for anti-doping detection in which BPC-157 was not administered to people. Such work must not be counted as a clinical exposure study. FDA PDF pp. 40 ↗

Reported adverse events cannot establish causation or incidence

FDA discussed injection-related reports but noted incomplete information and concomitant substances. Those reports neither prove that BPC-157 caused each event nor establish a reliable adverse-event rate. FDA PDF pp. 41, 44 ↗

What remains to be checked

  • Check subsequent advisory records and any final FDA action separately from the staff briefing.
  • Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA BPC-157 briefing for the July 2026 advisory meeting ↗

    Source dated 2026-05-11; retrieved 2026-09-16.

    • Briefing boundary and evaluation scope · PDF pp. 1, 5, 8, 9 of 68
    • Effectiveness evidence for ulcerative colitis · PDF pp. 25, 27, 28, 29 of 68
    • Safety conclusions and recommendation · PDF pp. 43, 44, 45, 46, 47 of 68

    SHA-256: 339602f311095bb9baa023f102186a659ea6871c3f5a4dc7f811036182764d14

  • FDA bpc-157 briefing for the July 2026 advisory meeting ↗

    Source dated 2026-07-23; retrieved 2026-09-19.

    • The ulcerative-colitis evidence was a short meeting abstract · PDF pp. 27, 28 of 68
    • Rectal-enema findings do not validate other formulations · PDF pp. 27, 40 of 68
    • Assay experiments are not human treatment studies · PDF pp. 40 of 68
    • Reported adverse events cannot establish causation or incidence · PDF pp. 41, 44 of 68

    SHA-256: 339602f311095bb9baa023f102186a659ea6871c3f5a4dc7f811036182764d14

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

219 retrieved · 2 included · 0 excluded · 217 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"BPC-157"[Title/Abstract] OR "BPC 157"[Title/Abstract] OR "Body protection compound 157"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:31.700553+00:00 · HTTP 200 · SHA-256 6b4b040b2928d5bedf68001b4b16a9790dc889d94c33f16a9cedcd6d3a336ed6.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.

Showing 25 of 219 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 40131143 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: bpc-157-PMID40131143-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 b8138b6d382044cd559c8274fa4c5cc83530afbdd3ba2e55ee069ce56d9a55ca.

  2. PubMed 40005999 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: bpc-157-PMID40005999-registry-linkage-unresolved.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 54a98f7cbdf10ee6109915e24f031cd8c0ab34ed2d0d58d07442b65b1b59ef77.

  3. PubMed 42667535 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42635865 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42578445 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42555375 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42542926 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42533460 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42385164 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42356491 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42328738 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42278509 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42222211 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42204242 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42198317 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42160466 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42123471 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42123221 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42021992 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 41966639 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 41901308 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 41898733 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 41832718 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 41754849 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 41754776 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"BPC-157"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:10.142395+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["BPC-157", "Body protection compound 157"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["BPC-157", "Body protection compound 157"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["BPC-157", "Body protection compound 157"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          4 retrieved · 0 included · 0 excluded · 4 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "BPC-157" OR "Body protection compound 157" OR "BPC 157"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:24:17.308653+00:00 · HTTP 200 · SHA-256 2c16cd37c068ecf54d683c5ec151c5ea6da64112f92b2318936d8b3f89f1226d.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 4 of 4 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          1. ClinicalTrials.gov NCT07437547 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          2. ClinicalTrials.gov NCT07752381 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          3. ClinicalTrials.gov NCT02637284 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          4. ClinicalTrials.gov NCT07803250 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of BPC-157?

          Not an FDA-approved drug. FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.↗↗↗↗

          The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          3
          Source years
          7
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Collection changes

          What did PeptideScanner add most recently?

          1. Literature metadata · added November 14, 2026

            BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.↗Source date September 29, 2026
          2. Clinical trials · added September 9, 2026

            ClinicalTrials.gov record NCT07803250↗Source date September 3, 2026
          3. Literature metadata · added September 9, 2026

            Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats.↗Source date December 30, 2020

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to BPC-157?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          53Selected dated records
          63Connected citations
          7Populated source years2017–2026
          3/4Record lanes present

          Registered human studies

          Trial composition

          1 of 2 selected trial records include at least one phase value; 1 of 2 include a status value in the retained structured contract.

          PhasesPhase 1 1
          Status at observationNot yet recruiting 1

          A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

          A status value is unavailable here for 1 selected record; this is not counted as a trial status.

          PubMed bibliography

          Publication composition

          24 of 49 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Publication typesJournal Article 24Review 9Research Support, Non-U.S. Gov't 3Comparative Study 2Validation Study 1

          Bibliography fields unavailable here for 25 selected records; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          1
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          53

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Source records by collection · 53 dated records

          Research hub

          Explore the BPC-157 evidence record

          Open all 53 records →
          53Dated records
          3Evidence types
          60Cited public sources
          7Source years

          Change ledger

          Recently changed for BPC-157

          Open all 55 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          BPC-157 profile

          We added a plain-language reader guide with cited answers, re-checked FDA’s BPC-157 records, added a second registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists BPC-157. FDA has not issued a final 503A rule.

          PeptideScanner change date
          November 14, 2026
          Evidence lane
          Profile
          Record added

          BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.

          PubMed lists PMID 42794771 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

          PeptideScanner change date
          November 14, 2026
          Cited source date
          September 29, 2026
          Evidence lane
          Literature metadata
          Record added

          ClinicalTrials.gov record NCT07803250

          PeptideScanner retained ClinicalTrials.gov record NCT07803250 at 2026-09-09T19:17:17.410Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was bpc-157.

          PeptideScanner change date
          September 9, 2026
          Cited source date
          September 3, 2026
          Evidence lane
          Clinical trials

          Official-source collections

          Source records for BPC-157

          Open the full research atlas →
          PubMed49

          24 with attributed title, venue, publication-date, and type metadata.

          1. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.International journal of molecular sciences · 2026 09 19
          2. Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats.Pharmaceuticals (Basel, Switzerland) · 2026 01 22
          3. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats.Pharmaceuticals (Basel, Switzerland) · 2026 01 14
          Explore all selected literature →

          Evidence types

          Coverage by source year

          Selected records span November 16, 2017 to September 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • U.S. Food and Drug Administration1,4
          • Hudson Biotech3
          • U.S. Department of Health and Human Services7

          Trial records

          Dated updates connected to this profile · 53

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Literature metadata

            BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.↗

            PubMed lists PMID 42794771 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          2. Clinical trials

            ClinicalTrials.gov record NCT07803250↗

            PeptideScanner retained ClinicalTrials.gov record NCT07803250 at 2026-09-09T19:17:17.410Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was bpc-157.↗

          3. Literature metadata

            PubMed record PMID 42555375↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42555375 at 2026-08-10T10:49:12.992Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          4. Literature metadata

            PubMed record PMID 40756949↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40756949 at 2026-08-10T10:49:06.956Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2025-08-04. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          5. Literature metadata

            PubMed record PMID 42278509↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42278509 at 2026-08-10T18:13:52.250Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          6. Literature metadata

            PubMed record PMID 42356491↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42356491 at 2026-08-10T18:13:53.763Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          7. Regulatory

            FDA committee met on seven peptide-related groups of bulk drug substances↗

            FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗

          8. Literature metadata

            PubMed record PMID 41898733↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 41898733 at 2026-08-10T18:13:46.758Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-03-28. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          9. Literature metadata

            PubMed record PMID 42385164↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42385164 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          10. Literature metadata

            PubMed record PMID 40789979↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 40789979 at 2026-07-30T16:14:11.079Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2025-08-11. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          11. Literature metadata

            PubMed record PMID 42198317↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42198317 at 2026-07-30T16:20:45.939Z. PubMed recorded a metadata revision date of 2026-05-29 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          12. Literature metadata

            PubMed record PMID 42123221↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42123221 at 2026-07-30T16:20:45.661Z. PubMed recorded a metadata revision date of 2026-05-15 and an Entrez history date of 2026-05-13. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            FDA briefing document for BPC-157-related bulk drug substances ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          2. 2
            Certain bulk drug substances for use in compounding that may present significant safety risks ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          3. 3
            BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗

            ClinicalTrials.gov · Official source · Source checked July 22, 2026

          4. 4
            July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

            U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

          5. 5
            ClinicalTrials.gov record NCT07803250 · retained source version 2026-09-03:67a2d48128fcdff7f261f5c04e4a69cfe170396b0726d611a8db06ad7256abc0 ↗

            ClinicalTrials.gov · Official source · Source checked September 9, 2026

          6. 6
            Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

            Federal Register via GovInfo · Official source · Source checked August 21, 2026

          7. 7
            Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

            Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

          8. 8
            HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

            U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026